FDA Qualifies Total Hip Bone Mineral Density As Surrogate Endpoint For Osteoporosis Drug Development
Dec 19 (Reuters) -
Source text: [ID:]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.